IR-MED and Dice Technologies Sign LOI to Bring PressureSafe to Japan

Medtronic plc is trading at roughly 14.4 times forward earnings at $86.38 per share after raising its fiscal 2027 organic revenue growth and diluted non-GAAP EPS outlook in September. The company now expects organic revenue growth of 7.25% to 7.75% and full-year diluted non-GAAP EPS of $5.94 to $6.00, following first-quarter non-GAAP diluted EPS of $1.45 that came in ahead of guidance. Fiscal 2027 first-quarter revenue rose 13.7% organically to $9.8 billion, though Medtronic estimated that an extra fiscal week in the quarter contributed approximately $570 million to organic growth, making the headline rate look stronger than underlying recurring growth. Cardiovascular led the quarter with organic revenue up 18.9%, including 88% growth in Cardiac Ablation Solutions and 29.1% growth in Electrophysiology Therapies, while Neuroscience rose 9.3%, Medical Surgical grew 10.2%, and Diabetes rose 14.9% organically. The company has also expanded through the acquisitions of Scientia Vascular and SPR Therapeutics and announced further investments in robotic-assisted surgery and leaflet modification technology. Medtronic shares have declined more than 7% over the past 12 months, compared with a 17% gain for the broader market.

Becton Dickinson's Revello Vascular Covered Stent hit the primary endpoint in iliac artery disease in nine-month results from the AGILITY trial. The clinical data arrived during a busy October for the company that also brought a new U.S. government manufacturing partnership and a leadership change in its Surgery unit, while a separate product recall underscored ongoing execution risk across the portfolio. The shares have gained 20.28% over the past 90 days even as the year-to-date share price return stands at a 6.25% decline, and the 1-year total shareholder return of 26.07% points to building momentum. The most followed valuation narrative puts Becton Dickinson's fair value at $195.67 against a last close of $182.75, implying the rally has not fully closed the gap those followers see. That narrative rests on a focused medtech portfolio in which more than 90% of revenue comes from businesses growing in the mid to high single digits, with platforms such as biologic drug delivery, Advanced Patient Monitoring, PureWick and advanced tissue regeneration growing at double digits, plus about $2.3b of share repurchases year to date in fiscal 2026, $3.1b returned to shareholders in total and $2.1b of debt retired while keeping net leverage around 2.9x. Becton Dickinson still faces real pressure if China weakness persists and if recalls or FDA actions around infection prevention products expand or take longer to resolve.

Sino Medical announced that its SCHONKYTONK coronary balloon dilatation catheter has received approval from Colombia's INVIMA and obtained a medical device registration certificate. The product is indicated for balloon catheter dilatation of stenotic segments of coronary arteries or stenosis at bypass graft sites to improve myocardial perfusion. The company stated that this approval is an important part of its overseas business expansion and will help drive overseas sales of the product.